References | CAYSTON® (aztreonam for inhalation solution)

  1. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91-100.

  2. Cystic Fibrosis Foundation. 2018 Patient Registry Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2018. Accessed April 9, 2020.

  3. Cystic fibrosis. US National Library of Medicine website. Updated March 31, 2020. Accessed April 9, 2020.

  4. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680-689.

  5. Pritt B, O’Brien L, Winn W. Mucoid Pseudomonas in cystic fibrosis. Am J Clin Pathol. 2007;128(1): 32-34.

  6. Basics of lung care. Cystic Fibrosis Foundation website. Accessed April 9, 2020.

  7. Cunningham JC, Taussig LM. Respiratory System. In: An Introduction to Cystic Fibrosis: For Patients and Their Families. 6th ed. Cystic Fibrosis Foundation; 2013:41-58.

  8. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009;135(5):1223-1232.

  9. Assael BM, Pressler T, Bilton D, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros. 2013;12(2):130-140.